Skip to main content
. 2022 Jun 21;4(1):vdac097. doi: 10.1093/noajnl/vdac097

Figure 1.

Figure 1.

Prognostic impact of PDGFRA and MGMTp status. (A) IDH wild-type glioblastoma (GBM) cases with PDGFRA gain/amplification exhibiting significantly shorter overall survival (OS) than those without PDGFRA gain/amplification. (B) IDH wild-type GBM cases with unmethylated MGMTp exhibiting significantly shorter OS than those with methylated MGMTp.